English
Back
Download
Log in to access Online Inquiry
Back to the Top

avatar
rmgm Private ID: 151673701
No profile added yet
Follow
    $Windtree Therapeutics (WINT.US)$
    - 60 million shares traded before 7 AM , float of 11 million
    - Biotech stock
    - Plan for Reverse stock split in the next few months
    - Analyst Rating in December was 7 $
    - Has been aggressively sold and shorted for the past 4 months even with good news being released then
    - Reached a low of 10 cents few days ago down from 3$ in September
    - 200 EMA is at 6$
    $Windtree Therapeutics (WINT.US)$  2 days in a row with daily high volume and big green candles  . Finally traders spotting this extremely oversold stock .
    $Windtree Therapeutics (WINT.US)$ Shit show of a stock , DCB after DCB , endless short selling . If analysts say it's worth 7$ and its trading for 16 cents then someone is either lying or just zero sentiment and massive short selling and not wanting to buy back . Pitty
    1
    $Windtree Therapeutics (WINT.US)$ Wish to see the short sellers getting squeezed once more in this stock like back in July/August 2024 . Analysts' rating is 7 $ few weeks ago !
    2
    $Windtree Therapeutics (WINT.US)$ What is going on with the volume on Thursday , nearly 100% of outstanding shares were traded , price barely moved up or down .
    They did announce a meeting in February though to vote on another reverse split
    $NuCana (NCNA.US)$ 20$ target price , 1.5 mil float and lowest ever now .
    1
    $Windtree Therapeutics (WINT.US)$  Analysts target price is 7 .  Hope soon for a DCB or strong rise on the next good news
    $Genprex (GNPX.US)$ Why selling it off this low , so oversold . analysts' target price is 7 $ . Sellers are just pushing this to another reverse stock split .
    $Hoth Therapeutics (HOTH.US)$ Will it break the 1 dollar premarket
    $Atara Biotherapeutics (ATRA.US)$ over 30 million cash in the books acccording to there 30th of June Financial report , will have additional extra cash of 36 million on 5 September from institutional investors and big pharma company by issuing them around 4 million shares at 8.25 $ , will further receive 20 million + 60 Million by Pierre Fabre Pharmaceuticals once FDA approves there EBV drug in Jan 2025 .
    Should see increased acitivity soon as all these large investors have interest in this comp...